Showing Results for
- Academic Journals (3,308)
Search Results
- 3,308
Academic Journals
- 3,308
-
From:Indian Journal of Pathology and Microbiology (Vol. 56, Issue 4) Peer-ReviewedByline: Priya. Dharmalingam, V. Roopesh Kumar, Surendra. Verma Background: Vascular endothelial growth factor (VEGF) expression has been extensively studied in astrocytoma, whereas relatively less literature exists...
-
From:Indian Journal of Medical and Paediatric Oncology (Vol. 31, Issue 4) Peer-ReviewedByline: S. Advani This article highlights the current knowledge of mTOR biology and provides new insights into the role of mTOR in different cancers. An active mTOR coordinates a response in cell growth directly...
-
From:Review of Optometry (Vol. 143, Issue 11) Peer-ReviewedAge-related macular degeneration (AMD) is the leading cause of severe vision loss in the Western world. (1) In the United States alone, advanced AMD affects more than 1 million people, and approximately 8 million more...
-
From:Chest (Vol. 128, Issue 6) Peer-ReviewedAbbreviations: GTN = glyceryl trinitrate; NO = nitric oxide; PAH = pulmonary arterial hypertension Dysfunction of pulmonary endothelial cells plays an important role in the pathogenesis of pulmonary arterial...
-
From:Ophthalmology Times (Vol. 40, Issue 15) Peer-ReviewedST. LOUIS, MO :: ANTI-VASCULAR ENDOTHELIAL growth factor (VEGF) treatments for diabetic macular edema (DME) have not worked as well in clinical practice as in clinical trials, according to one clinician....
-
From:Nature Medicine (Vol. 22, Issue 11) Peer-ReviewedAuthor(s): Kyrre E Emblem (corresponding author) [1]; Rakesh K Jain [2] Since 2004, a dozen drugs that target either VEGFA or its receptors have been approved for the treatment of ten different malignancies. In...
-
From:PLoS ONE (Vol. 7, Issue 5) Peer-ReviewedAuthor(s): Jian Kong 1 , Jinge Kong 2 , Bing Pan 2 , Shan Ke 1 , Shuying Dong 1 , Xiuli Li 3 , Aimin Zhou 4 , Lemin Zheng 2 , * , Wen-bing Sun 1 , * Introduction Hepatocellular carcinoma (HCC) is the fifth most...
-
From:PLoS ONE (Vol. 7, Issue 12) Peer-ReviewedAuthor(s): Anna Riese 1 , Yvonne Eilert 1 , Yvonne Meyer 1 , Meral Arin 1 , Jens M. Baron 2 , Sabine Eming 1 , Thomas Krieg 1 , Peter Kurschat 1 , * Introduction Like no other organ the human skin as the outer...
-
From:PLoS ONE (Vol. 8, Issue 6) Peer-ReviewedAuthor(s): Judith Brouwers 1, Rintis Noviyanti 2, Rob Fijnheer 1, Philip G. de Groot 1, Leily Trianty 2, Siti Mudaliana 2, Mark Roest 1, Din Syafruddin 2, Andre van der Ven 3, Quirijn de Mast 1,3,* Introduction...
-
From:PLoS ONE (Vol. 9, Issue 2) Peer-ReviewedAuthor(s): Lun Wu 1, Zhihao Fu 1, Shiji Zhou 2, Jianping Gong 1, Chang An Liu 1, Zhengrong Qiao 3, Shengwei Li 1,* Introduction Hepatocellular carcinoma (HCC) is the sixth most common cancer, and the third most...
-
From:PLoS ONE (Vol. 9, Issue 3) Peer-ReviewedAuthor(s): Xuejun Sun 1, Bo Fang 1, Xi Zhao 1, Guangwei Zhang 2, Hong Ma 1,* Introduction Bone marrow mesenchymal stem cells (MSCs) transplantation is an attractive therapeutic method for tissue injuries, such as...
-
From:PLoS ONE (Vol. 9, Issue 2) Peer-ReviewedAuthor(s): Wenbo Meng 1,2, Xun Li 3,*, Zhongtian Bai 3, Yan Li 4, Jinqiu Yuan 5, Tao Liu 1, Jun Yan 3, Wence Zhou 3, Kexiang Zhu 3, Hui Zhang 3, Yumin Li 1,* Introduction Human hepatocellular carcinoma (HCC) is...
-
From:PLoS ONE (Vol. 8, Issue 8) Peer-ReviewedAuthor(s): Anna Burford 1,2, Suzanne E. Little 1,2, Alexa Jury 1,2, Sergey Popov 1,2, Ross Laxton 3, Lawrence Doey 3, Safa Al-Sarraj 3, Juliane M. Jürgensmeier 4, Chris Jones 1,2,* Introduction Molecular profiling...
-
From:PLoS ONE (Vol. 7, Issue 9) Peer-ReviewedAuthor(s): Markus Wagegg 1 , 2 , 3 , Timo Gaber 1 , 2 , 3 , * , Ferenz L. Lohanatha 1 , 2 , 3 , Martin Hahne 1 , 2 , 6 , Cindy Strehl 1 , 2 , Monique Fangradt 1 , 2 , Cam Loan Tran 1 , 2 , Kerstin Schönbeck 1 , 2 ,...
-
From:Ophthalmology Times (Vol. 42, Issue 9) Peer-ReviewedANTI-VEGF THERAPY for Zone I retinopathy of prematurity (ROP) is associated with better structural and functional outcomes than laser therapy, but also a longer recurrence risk period, said Helen A. Mintz-Hittner, MD....
-
From:PLoS ONE (Vol. 7, Issue 8) Peer-ReviewedAuthor(s): Magalie Vatin 1 , Gaetan Burgio 2 , 3 , Gilles Renault 1 , Paul Laissue 4 , Virginie Firlej 1 , Françoise Mondon 1 , Xavier Montagutelli 2 , Daniel Vaiman 1 , Catherine Serres 1 , Ahmed Ziyyat 1 , *...
-
From:Lung (Vol. 196, Issue 2) Peer-ReviewedAuthor(s): Takeshi Saraya 1 , Kosuke Ohkuma 1 , Takayasu Watanabe 1 , Sunao Mikura 1 , Fumi Kobayashi 1 , Junpei Aso 1 , Hiroki Nunokawa 1 , Kojiro Honda 1 , Yukari Ogawa 1 , Masaki Tamura 1 , Mitsuru Sada 1 , Miku Oda...
-
From:Journal of Ophthalmology (Vol. 2017) Peer-ReviewedPurpose. To evaluate the response of intravitreal aflibercept injection (IAI) in eyes with detachment of retinal pigment epithelium (DEP) secondary to nAMD refractory to monthly ranibizumab. Patients and Methods. This...
-
From:Nature Medicine (Vol. 8, Issue 7) Peer-ReviewedRespiratory distress syndrome (RDS) due to insufficient production of surfactant is a common and severe complication of preterm delivery. Here, we report that loss of the hypoxia-inducible transcription factor-2[alpha]...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 33, Issue 1) Peer-ReviewedAuthor(s): Mitsuro Kanda1 , Shuji Nomoto1 , Hisaharu Oya1 , Dai Shimizu1 , Hideki Takami1 , Soki Hibino1 , Ryoji Hashimoto1 , Daisuke Kobayashi1 , Chie Tanaka1 , Suguru Yamada1 , Tsutomu Fujii1 , Goro Nakayama1 ,...